Radiotherapy and temozolomide in anaplastic astrocytoma: A retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)

Neuro-Oncology

Volumn 14, Issue 6, 2012, Pages 798-807

  Scoccianti, Silvia ^a   Magrini, Stefano Maria ^b   Ricardi, Umberto ^c   Detti, Beatrice ^a   Krengli, Marco ^d   Parisi, Salvatore ^e   Bertoni, Filippo ^f   Sotti, Guido ^g   Cipressi, Samantha ^a   Tombolini, Vincenzo ^h   Dall'Oglio, Stefano ⁱ   Lioce, Marco ^d   Saieva, Calogero ^k   Buglione, Michela ^b   Mantovani, Cristina ^c   Rubino, Giovanni ^l   Muto, Paolo ^m   Fusco, Vincenzo ⁿ   Fariselli, Laura ^o   De Renzis, Costantino ^p   Masini, Laura ^j   Santoni, Riccardo ^q   Pirtoli, Luigi ^l   Biti, Giampaolo ^a   more..

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY HOSPITAL OF VERONA   (Italy)

^j NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^k CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^l UNIVERSITY OF SIENA   (Italy)

^m Radioterapia   (Italy)

ⁿ REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^o DEPARTMENT OF NEUROSURGERY   (Italy)

^p UNIVERSITY OF MESSINA   (Italy)

^q UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

anaplastic astrocytoma; chemotherapy; radiotherapy; temozolomide; WHO grade III gliomas

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGE; AGED; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862182813     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos081     Document Type: Review

References (35)

1. Magrini SM, Ricardi U, Santoni R, et al. Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. Int J Radiat Oncol Biol Phys. 2006;65:788-799. (Pubitemid 43795845)
2. Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67:446-458.
3. Stupp R, Mason WP, Van Den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;52:987-996. (Pubitemid 40349501)
4. DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol. 2009;27:5861-5862.
5. Omar A, Mason WP. Temozolomide: the evidence for its therapeutic efficacy in malignant astrocytoma. Core Evid. 2009;4:93-111.
6. Dresemann G. Temozolomide in malignant glioma. Oncotargets Ther. 2010;3:139-146.
7. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710. (Pubitemid 23133591)
8. Hildebrand J, Gorlia T, Kros JM, et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008;44:1210-1216.
9. Medical Research Council Brain tumor Working Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma . J Clin Oncol. 2001;19:509-518.
10. WickW, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-5880.
11. Gilbert MR, Friedman HS, Kuttesch JF, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol. 2002;4:261-267.
12. Brada M, Ashley S, Dowe A, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol. 2005;16:942-949. (Pubitemid 40903921)
13. Chang SM, Prados MD, Yung WKA, et al. Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma. A North American Brain Tumor Consortium trial. Cancer. 2004;100:1712-1716. (Pubitemid 38456350)
14. Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8:253-260. (Pubitemid 46542650)
15. Combs SE, Nagy M, Edler L, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiother Oncol. 2008;88:177-182.
16. Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol. 2007;63:72-80. (Pubitemid 46810281)
17. Tortosa A, Vinolas N, Villa S, et al. Prognostic implication of clinical, radiologic and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97:1063-1071. (Pubitemid 36173159)
18. Perry A, Jenkins RB, O'Fallon JR, et al. Clinicopathological study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content, cellular proliferation and p53 expressions. Cancer. 1996;86:672-683. (Pubitemid 29379414)
19. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA. Prognostic factors for anaplastic astrocytomas. J Neurooncol. 2007;81:295-303. (Pubitemid 46165334)
20. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and the timing of radiation. J Clin Oncol. 1997;15:1294-1301. (Pubitemid 27167360)
21. van Veelen MLC, Avezaat CJJ, Kros JM, et al. Supratentorial low-grade astrocytoma: Prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psych. 1998;64: 581-587. (Pubitemid 28204142)
22. Krzyszkowski T, Czepko R, Betlej M. Prognostic value of epileptic seizures in patients with cerebral gliomas. Ann Acad Med Stetin. 2004;50:35-40.
23. Park CK, Lee SH, Han JH, et al. Recursive partitioning analysis of prognostic factors inWHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer. 2009;9:450-456.
24. Paravati AJ, Heron DE, Landsittel D, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol. 2011;104:339-349.
25. Cohen ZR, Suki D, Shi W, et al. Surgical resection of anaplastic astrocytoma: prognostic factors and outcome. Neuro-Oncol. 2002;4:367.
26. Mc Girt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110:156-162.
27. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
28. Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11:5167-5174. (Pubitemid 41003702)
29. Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol. 2006;60:99-111. (Pubitemid 44636249)
30. Kreth S, Thon N, Eigenbrod S, et al. O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. Plos One. 2011;6:e17156.
31. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol. 2008;115:249-259.
32. Felsberg J, Thon N, Eigenbrod S, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011;129:659-670.
33. Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in cancer patient. Cancer Chemother Pharmacol. 2011;67:489-501.
34. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30:1385-1407.
35. Grossman SA, Ye X, Lesser GJ, et al. Iatrogenic Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473-5480.